{
  "abstract": "Purpose\n\nBrentuximab vedotin (BV) represents a therapeutic advancement in the treatment of CD30-positive lymphomas, yet its clinical utility is often limited by BV-induced peripheral neuropathy (PN). Currently, evidence-based, BV-specific guidelines for the assessment and management of PN are scarce, resulting in variability in clinical practice. This study aimed to establish international expert consensus on the optimal assessment, monitoring and management strategies for BV-induced PN in patients with lymphoma.Methods\n\nA modified Delphi panel was conducted, engaging a total of 13 experts from eight different countries and representing haematology, neurology, dermatology, nursing and allied health disciplines. Panellists participated in three rounds of structured surveys, with statements developed based on a targeted literature review and guidance from an expert steering committee. Consensus was defined as ≥ 70% agreement/disagreement. Consensus was achieved on 60/87 (69%) statements across domains including risk factor assessment, symptom monitoring, pharmaceutical and non-pharmaceutical management.Results\n\nKey recommendations include routine risk profiling before BV initiation, use of validated assessment tools at baseline and throughout therapy, multidisciplinary collaboration, and early intervention for worsening PN. Areas of uncertainty and variability in PN management remain, particularly regarding management of intermediate-grade PN and optimal non-pharmacological strategies.Conclusion\n\nThese international consensus recommendations provide practical guidance for improving clinical management of BV-induced PN and highlight the importance of early identification, personalised care and multidisciplinary collaboration. Further research is needed to address persistent gaps and inform future clinical guidelines.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Neurology, Institut Català d'Oncologia-Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain. rvelascof@bellvitgehospital.cat.",
    "Department of Cell Biology, Physiology and Immunology, Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Universitat Autònoma de Barcelona, Bellaterra, Spain. rvelascof@bellvitgehospital.cat.",
    "University of Sao Paulo Medical School, Sao Paulo, Brazil.",
    "Agios Andreas General Hospital of Patras, Patras, Greece.",
    "Università Di Milano-Bicocca, Monza, Italy.",
    "Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy.",
    "Institut Catala d'Oncologia, Hospital Duran Reynals Barcelona, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.",
    "Oslo University Hospital, Oslo, Norway.",
    "Clínica Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.",
    "University Costa del Sol Hospital Marbella, Málaga, Spain.",
    "School of Psychology, Health & Clinical Sciences at, Aston University, Birmingham, UK.",
    "University Hospital 12 de Octubre, Institute i+12 Medical School, University Complutense, Madrid, Spain.",
    "Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.",
    "University of Birmingham, Birmingham, UK.",
    "Guy's and St Thomas' NHS Foundation Trust, London, UK.",
    "School of Nursing, The Hong Kong Polytechnic University, Hong Kong, Hong Kong.",
    "Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.",
    "Epworth Healthcare, Victoria, Australia."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 16,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Roser Velasco"
    },
    {
      "affs": [
        2
      ],
      "name": "José A Sanches"
    },
    {
      "affs": [
        3
      ],
      "name": "Andreas A Argyriou"
    },
    {
      "affs": [
        4,
        5
      ],
      "name": "Guido Cavaletti"
    },
    {
      "affs": [
        6
      ],
      "name": "Eva Domingo-Domenech"
    },
    {
      "affs": [
        7
      ],
      "name": "Alexander Fosså"
    },
    {
      "affs": [
        8
      ],
      "name": "Jaime Gállego Pérez-Larraya"
    },
    {
      "affs": [
        9
      ],
      "name": "Antonia Miranda Ruiz"
    },
    {
      "affs": [
        10
      ],
      "name": "Alex Molassiotis"
    },
    {
      "affs": [
        2
      ],
      "name": "André Neder Ramires Abdo"
    },
    {
      "affs": [
        11
      ],
      "name": "Pablo L Ortiz-Romero"
    },
    {
      "affs": [
        12
      ],
      "name": "Susanna B Park"
    },
    {
      "affs": [
        13
      ],
      "name": "Julia Scarisbrick"
    },
    {
      "affs": [
        14
      ],
      "name": "Lauren Urwin"
    },
    {
      "affs": [
        15
      ],
      "name": "Mian Wang"
    },
    {
      "affs": [
        16,
        17
      ],
      "name": "H Miles Prince"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/92qktw0emyxjk.bib",
  "cited_by": 0,
  "doi": "10.1007/s00520-026-11314-5",
  "fulltext_url": "https://europepmc.org/articles/PMC13676650",
  "id": "92qktw0emyxjk",
  "issns": [
    "0941-4355",
    "1433-7339"
  ],
  "landing_url": "https://europepmc.org/article/MED/42891686",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2730|Cancer Treatment and Pharmacology"
    ]
  ],
  "openalex": "W7222844006",
  "pdf_url": "https://europepmc.org/articles/PMC13676650?pdf=render",
  "pmcid": "PMC13676650",
  "pmid": "42891686",
  "published": "2026-10-17",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/92qktw0emyxjk.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:18:46Z",
      "native_id": "MED:42891686",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42891686"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer Treatment and Pharmacology",
      "subfield": "oncology"
    }
  ],
  "title": "Expert consensus on the management of peripheral neuropathy in patients with lymphoma on brentuximab vedotin.",
  "title_text": "Expert consensus on the management of peripheral neuropathy in patients with lymphoma on brentuximab vedotin.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:18:46Z",
  "url": "https://research.draconitic.com/paper/92qktw0emyxjk",
  "venue": "Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer",
  "versions": []
}